Curis Begins Phase 1 Trial of Anti-Tumor Drug
Drug developer Curis (NASDAQ:CRIS), of Cambridge, MA, reported today that it has begun a Phase 1 clinical trial of an anti-cancer small molecule, dubbed CUDC-101. The experimental drug is designed to inhibit tumor cell growth and survival, and 18 to 40 patients are expected to enroll in the clinical trial.
More from EXOME
Trending on Xconomy
By posting a comment, you agree to our terms and conditions.
Underwriters and Partners
Xpertise: Watch + Learn
Xconomy Insight · Special Report
Starting a Biotech Company: What Every Entrepreneur Needs to Know
Success or failure depends on you. Get advice from the experts to help your startup succeed
From Our Advertisers
Corporate Venture Capital is on the Rise in Wisconsin
CVC provides new funding source for startups
Wisconsin Economic Development Corporation
The Threat of a Black Market Within the Market
The Hidden Risks of Sourcing Human Biological Samples
Scientist.com